What is OptimizeRx's 2029?

OptimizeRx (OPRX) reported 2029 of $3.71M in Q1 2026.

What is the long-term trend for OptimizeRx's 2029?

Over 4 years (2020 to 2024), OptimizeRx's 2029 has grown at a 38.6% compound annual growth rate (CAGR), from $1.06M to $3.91M.

OptimizeRx OPRX 2029

2029 at other companies

Veeva SystemsVEEV

——

DoximityDOCS

——

Teads Holding Co. Common StockTEAD

——

TruBridge, Inc.TBRG

——

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's 2029?: OptimizeRx (OPRX) reported 2029 of $3.71M in Q1 2026.
What is the long-term trend for OptimizeRx's 2029?: Over 4 years (2020 to 2024), OptimizeRx's 2029 has grown at a 38.6% compound annual growth rate (CAGR), from $1.06M to $3.91M.